# Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

> **NCT06434350** · PHASE1,PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 41 (estimated)

## Conditions studied

- Advanced Bladder Cancer

## Interventions

- **DRUG:** Enfortumab Vedotin
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT06434350
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-10
- **Primary completion:** 2027-09-24
- **Final completion:** 2027-09-24
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06434350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06434350, "Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06434350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*